Cargando…

PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis

Gene amplifications of PIK3CA or KRAS induce a downstream activation of the AKT-mTOR or RAF-ERK-pathways. Interactions of the active AKT pathway have been implicated in the inflammatory tumor microenvironment. Nothing is known about these interactions or prognostic power in esophageal adenocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Essakly, Ahlem, Loeser, Heike, Kraemer, Max, Alakus, Hakan, Chon, Seung-Hun, Zander, Thomas, Buettner, Reinhard, Hillmer, Axel M., Bruns, Christiane J., Schroeder, Wolfgang, Gebauer, Florian, Quaas, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2019
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931191/ https://www.ncbi.nlm.nih.gov/pubmed/31865178 http://dx.doi.org/10.1016/j.tranon.2019.10.013

Ejemplares similares

Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma
por: Schallenberg, Simon, et al.
Publicado: (2020)

GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy
por: Plum, Patrick Sven, et al.
Publicado: (2020)

Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas
por: Rehkaemper, Jan, et al.
Publicado: (2020)

Y Chromosome Loss Is a Frequent Event in Barrett’s Adenocarcinoma and Associated with Poor Outcome
por: Loeser, Heike, et al.
Publicado: (2020)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018)

Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma
por: Loeser, Heike, et al.
Publicado: (2020)

Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies
por: Moentenich, Valeska, et al.
Publicado: (2020)

Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies
por: Moentenich, Valeska, et al.
Publicado: (2020)

The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma
por: Loeser, Heike, et al.
Publicado: (2019)

HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma
por: Plum, Patrick Sven, et al.
Publicado: (2019)

Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival
por: Loeser, Heike, et al.
Publicado: (2020)

Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma
por: Gebauer, Florian, et al.
Publicado: (2020)

Occurrence of High Microsatellite-Instability/Mismatch Repair Deficiency in Nearly 2,000 Human Adenocarcinomas of the Gastrointestinal Tract, Pancreas, and Bile Ducts: A Study From a Large German Comprehensive Cancer Center
por: Quaas, Alexander, et al.
Publicado: (2021)

Optimized PD-L1 scoring of gastric cancer
por: Schoemig-Markiefka, Birgid, et al.
Publicado: (2021)

Sex-specific prognostic effect of CD66b-positive tumor-infiltrating neutrophils (TANs) in gastric and esophageal adenocarcinoma
por: Quaas, Alexander, et al.
Publicado: (2021)

Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target
por: Loeser, Heike, et al.
Publicado: (2017)

Dickkopf-2 (DKK2) as Context Dependent Factor in Patients with Esophageal Adenocarcinoma
por: Schiffmann, Lars M., et al.
Publicado: (2020)

FGFR2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract
por: Albin, Jan, et al.
Publicado: (2022)

High protein and mRNA expression levels of TUBB3 (class III ß-tubulin) are associated with aggressive tumor features in esophageal adenocarcinomas
por: Loeser, Heike, et al.
Publicado: (2017)

Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus
por: Schoemmel, M., et al.
Publicado: (2021)

The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis
por: Simon, Adrian Georg, et al.
Publicado: (2023)

Dissecting the inflammatory tumor microenvironment of esophageal adenocarcinoma: mast cells and natural killer cells are favorable prognostic factors and associated with less extensive disease
por: dos Santos Cunha, Alyne Condurú, et al.
Publicado: (2023)

Integrin beta1 (ITGB1) as a prognostic marker in esophageal adenocarcinoma
por: Damanakis, Alexander I., et al.
Publicado: (2022)

Tumour area infiltration and cell count in endoscopic biopsies of therapy-naive upper GI tract carcinomas by QuPath analysis: implications for predictive biomarker testing
por: Scheel, Andreas H., et al.
Publicado: (2023)

Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus
por: Hoppe, Sascha, et al.
Publicado: (2022)

Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma
por: Quaas, Alexander, et al.
Publicado: (2019)

Cell type‐specific transcriptomics of esophageal adenocarcinoma as a scalable alternative for single cell transcriptomics
por: Krämer, Max, et al.
Publicado: (2020)

Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data
por: Hescheler, Daniel A., et al.
Publicado: (2020)

Two decades of gastric and gastroesophageal junction cancer surgery
por: Plum, Patrick S., et al.
Publicado: (2023)

Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction
por: Gebauer, Florian, et al.
Publicado: (2023)

Fructose-1,6-bisphosphatase 1 (FBP1) is an independent biomarker associated with a favorable prognosis in esophageal adenocarcinoma
por: Damanakis, Alexander, et al.
Publicado: (2022)

Combined score of Y chromosome loss and T-cell infiltration improves UICC based stratification of esophageal adenocarcinoma
por: Raters, Verena Maria, et al.
Publicado: (2023)

Aldo-Keto Reductase 1C3 Mediates Chemotherapy Resistance in Esophageal Adenocarcinoma via ROS Detoxification
por: Zhou, Chenghui, et al.
Publicado: (2021)

Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence
por: Pasternack, Helen, et al.
Publicado: (2018)

Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer
por: Schiffmann, Lars Mortimer, et al.
Publicado: (2018)

Upregulation of miR-17-92 cluster is associated with progression and lymph node metastasis in oesophageal adenocarcinoma
por: Plum, Patrick Sven, et al.
Publicado: (2019)

Extension of resection after positive intraoperative pathology during surgery for gastric and gastroesophageal junction adenocarcinoma: a retrospective cohort study
por: Plum, Patrick S., et al.
Publicado: (2023)

Improved Tissue Processing in Esophageal Adenocarcinoma After Ivor Lewis Esophagectomy Allows Histological Analysis of All Surgically Removed Lymph Nodes with Significant Effects on Nodal UICC Stages
por: Quaas, A., et al.
Publicado: (2020)

PIK3CA Amplification Is Common in Left Side-Tubular Adenomas but Uncommon Sessile Serrated Adenomas Exclusively with KRAS Mutation
por: Lee, Hyunsu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4btl0jiv3kfpur8o999ce868k2